Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / LLY

Stock rating · Pharmaceutical Preparations

Eli Lilly & Co. (LLY) Stock Rating & Analysis

As of November 20, 2026, MELANY rates Eli Lilly & Co. 68 out of 100 (Favorable). Its highest factor score is earnings track record at 100, and its lowest is valuation at 30.

MELANY ratingRated 2026-11-20

LLY · composite score

68/100
Favorable
Nov 20
Rating date
Live price in the app →
Quality86
Momentum77
Risk-adjusted75
Source basis SEC filings and live market dataDated snapshot

About Eli Lilly & Co.

Eli Lilly is a drug firm focused on neuroscience, cardiometabolic disease, cancer, and immunology. Its key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic conditions; and Taltz and Olumiant for immunology.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why LLY scores 68/100

LLY's 8 factor scores run from 30 to 100, and 5 of them sit above its composite of 68. Here is how LLY breaks down.

Valuation30/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

  • Forward P/E 26.5x, earnings growth accelerating
Business quality86/100

Margins, returns on capital, and balance-sheet strength.

  • Gross margin 84%
  • ROE 86%
Price momentum77/100

Direction and relative strength of the recent share-price trend.

  • Price +6.3% above 50-day MA
  • 50-day MA above 200-day (golden cross zone)
Earnings track record100/100

History of beating or missing estimates, and where estimates are heading.

  • Beat EPS estimates 4 of last 4 quarters
  • Avg EPS beat +24%
Analyst sentiment81/100

What Wall Street price targets and revisions are signalling.

  • Institutional net buying +13.9%
Catalyst setup36/100

Near-term events that could move the stock.

Risk-adjusted profile75/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How LLY compares

As of November 20, 2026, Eli Lilly & Co. ranks 2nd of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 55.

Also ranked in Healthcare Stocks. All stock rating pages.

Key risks for LLY

  • Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt

Sector and theme context

Eli Lilly & Co. sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 97/100 for strength. Theme strength feeds LLY's momentum and catalyst factors above.

LLY trade plan (Pro)

MELANY has a full position plan for Eli Lilly & Co.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates LLY

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Eli Lilly & Co.'s 68/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about LLY

Is Eli Lilly & Co. (LLY) a buy?

As of 2026-11-20, MELANY rated Eli Lilly & Co. Favorable with a composite score of 68/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does LLY rank against similar companies?

As of November 20, 2026, Eli Lilly & Co. ranks 2nd of 20 in MELANY's GLP-1, Obesity and Biotech Stocks list, where the average score is 55. Among the other names in the list, the highest scores belong to REGN (74) and ALNY (63).

Should I buy Eli Lilly & Co. stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Eli Lilly & Co. (LLY) Favorable with a composite of 68/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the LLY stock price forecast?

MELANY does not publish price targets or forecasts for LLY. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 68/100 across eight factors for Eli Lilly & Co., and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for LLY as of 2026-11-20: its analyst sentiment factor is 81/100 (Institutional net buying +13.9%), and its price momentum factor is 77/100.

Is LLY stock overvalued or undervalued?

MELANY's valuation factor currently reads 30/100 for Eli Lilly & Co., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives LLY's read.

What price should I buy LLY at?

Rather than chasing the current price, MELANY computes a smart entry zone for LLY: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying LLY stock?

The top risks MELANY currently flags for Eli Lilly & Co.: Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Eli Lilly & Co. a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 86/100 for Eli Lilly & Co., and earnings track record, at 100/100. The 68/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will LLY stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 77/100 for LLY right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this LLY rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores LLY as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, LLY included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.